Invus Financial Advisors

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Tasca is a biotechnology company that offers small molecule drugs for hard-to-treat oncology indications.

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.

Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics to target high-value, validated oncogenic drivers. It employs structure-guided drug discovery and advanced computational chemistry to create small-molecule therapies that selectively address oncogenic alterations, with the aim of improving patient outcomes in cancer.

Pi Health is a technology company specializing in streamlining oncology clinical trials. It offers a global, secure, and compliant platform that integrates various systems, enabling life sciences companies to identify suitable trial sites, manage them efficiently, and accelerate the development of lifesaving medicines. This, in turn, enhances patient access to cancer care and research, and facilitates the inclusion of diverse patient populations in clinical trials.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Founded in 2016, Health Data Analytics Institute develops an AI-based platform that leverages EHR data for real-time assessments of patient risk factors such as mortality, readmission, complications, and disease progression. Serving healthcare clients, the company aims to improve care delivery and population health while reducing costs.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

BelliWelli is a Los Angeles-based company founded in 2020 that specializes in gut-friendly, plant-based snack bars designed for individuals with irritable bowel syndrome (IBS). The company offers a range of gluten-free, dairy-free, and low-sugar bars that are certified low-FODMAP, providing a healthy snacking option for those managing digestive sensitivities. BelliWelli's products, made with ingredients like almond butter, chia seeds, and cinnamon, aim to enhance consumer awareness of IBS while promoting digestive health through the inclusion of probiotics in their snacks.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Aravive Biologics is a clinical-stage biotechnology company based in Houston, Texas, founded in 2008. The company specializes in developing novel cancer therapeutics aimed at treating various types of malignancies, including solid tumors and hematologic cancers. Aravive's approach involves targeting critical survival pathways, with a key therapeutic candidate designed to act as a decoy that binds to the GAS6 pathway with high affinity, thereby preventing the activation of the AXL signaling pathway. This strategy is intended to inhibit cancer cell growth and survival.

Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

Sironax is a clinical‑stage biotechnology company that develops therapies for age‑related degenerative diseases. The company focuses on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation, aiming to shift the treatment paradigm for these conditions. Its research includes apoptosis and other cell‑death pathways to create advanced pharmaceuticals for inflammatory and neurodegenerative diseases. Founded in 2017, Sironax is headquartered in Beijing, China.

AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Abata Therapeutics is a biotechnology company dedicated to developing innovative cell therapies for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. The company specializes in the manipulation of regulatory T cells (Tregs) to address these conditions, aiming to restore balance within the immune system. By engineering Tregs to precisely target disease-related antigens, Abata Therapeutics creates therapies that can effectively treat diseases such as multiple sclerosis and type 1 diabetes without imposing systemic immune suppression. Founded by experts in immunology and cell therapy, Abata is committed to translating advanced scientific research into meaningful therapies that improve the lives of individuals facing chronic autoimmune challenges.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Repertoire Immune Medicines, Inc. is a clinical stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company focuses on harnessing the power of T cells to develop innovative treatments for cancer, autoimmune diseases, and infectious diseases. By utilizing autologous T cells that are primed against specific cancer antigens and tethered to IL-15, Repertoire Immune Medicines aims to unlock and direct the human immune system to effectively prevent and treat various conditions. The company also specializes in characterizing T cell receptor (TCR)-antigen pairs and rationally designing targeted immune medicines, thereby enhancing the potential for effective therapies in serious health challenges.

Omega Therapeutics, Inc. is a development-stage biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in developing genomic medicines aimed at curing diseases through precision tuning of the human genome. It utilizes its proprietary epigenomic programming platform to engineer a new class of programmable epigenetic medicines known as Omega Epigenomic Controllers. These controllers are designed to selectively regulate genomic activity, allowing for the downregulation or upregulation of genes to achieve therapeutic effects. Omega Therapeutics seeks to transform human medicine by harnessing the natural capacity of the genome to treat and cure various diseases.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Faze Medicines is a biotechnology company focused on developing small molecule therapies that target biomolecular condensates to address the underlying biology of disease. It uses screening and proteomics to define condensate interaction networks and identify therapeutic candidates aimed at cellular mechanisms implicated in conditions such as amyotrophic lateral sclerosis and myotonic dystrophy type 1, with research extending to other diseases including frontotemporal dementia. Founded in 2020 and based in Cambridge, Massachusetts.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative, patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with significant unmet medical needs. Incorporated in 2015, Imvax's primary product, IGV-001, is an autologous tumor cell vaccine designed to harness the patient's immune system to generate a robust response against tumor cells. The company employs advanced methodologies, including patient cell harvest and treatment, immunogenic cell death, and activation of both the innate and adaptive immune systems, to enhance therapeutic outcomes. Through its novel approach, Imvax aims to provide effective treatments for patients facing challenging cancer diagnoses.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Founded in 2016, Health Data Analytics Institute develops an AI-based platform that leverages EHR data for real-time assessments of patient risk factors such as mortality, readmission, complications, and disease progression. Serving healthcare clients, the company aims to improve care delivery and population health while reducing costs.

Viseon, Inc. is a medical device company based in Irvine, California, dedicated to advancing Minimally Invasive Spine Surgery (MISS) through innovative technology. Established in 2017 as a spin-out from Rebound Therapeutics Corporation, Viseon has developed the Voyant technology, which serves as a single-use, disposable alternative to traditional surgical microscopes, endoscopes, and loupes. This technology enhances surgical visualization by projecting the operative field onto a high-definition flat panel display, facilitating both in-room and remote observation. Viseon has made significant strides in product development, assembling a world-class Scientific Advisory Board and securing 13 patents to strengthen its intellectual property. The company is poised to begin human-use studies following a series of pre-clinical trials, aiming to improve procedural and clinical outcomes in spine surgery.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Triplet Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for triplet repeat expansion disorders, such as Huntington's disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these conditions at their source by utilizing a unique approach that involves a single oligonucleotide targeting the DNA Damage Response pathway. This strategy is designed to provide effective treatments for multiple repeat expansion disorders, enabling healthcare professionals to offer advanced biotherapeutic options to their patients. Through its research and development efforts, Triplet Therapeutics is committed to transforming the landscape of treatment for these challenging genetic disorders.

Inotrem is a biotechnology company specializing in immunotherapy for acute and chronic inflammatory syndromes. It has developed a proprietary technology platform targeting the TREM-1 pathway to control unbalanced inflammatory responses, leading to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in septic shock and myocardial infarction.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

BioNTech is a Germany-based biotechnology company focused on developing cancer therapeutics and vaccines for infectious diseases. Its portfolio includes mRNA-based therapies to encode antigens and neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. The company maintains an oncology pipeline and collaborates on vaccines for infectious diseases, including a COVID-19 vaccine developed with Pfizer.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

AlloVir is a biopharmaceutical company focused on developing allogeneic T-cell therapies to combat viral diseases. Its proprietary virus-specific T cell (VST) therapy platform enables the creation of off-the-shelf VSTs, designed to restore immunity in patients with T cell deficiencies at risk from life-threatening viral infections.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, Foghorn aims to manipulate gene expression to develop therapies for cancer and other serious diseases. The company is advancing multiple drug candidates, including FHD-286, a small-molecule enzymatic inhibitor designed for treating acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. Additionally, Foghorn is engaged in preclinical and discovery programs that focus on selectively targeting BRM in non-small-cell lung cancer and developing modulators for ARID1B in bladder, ovarian, and endometrial cancers. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics collaborates with Merck Sharp & Dohme Corp. to explore novel oncology therapeutics.

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immune-therapeutics targeting infectious diseases and cancers using its proprietary arenavirus platform. Its lead product candidates include HB-101 for cytomegalovirus prevention in transplant patients, and HB-201/HB-202 for human papillomavirus-positive cancers.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company based in Atlanta, Georgia, founded in 2007. The company specializes in the discovery and development of novel therapeutics aimed at treating inflammatory diseases, including cystic fibrosis and moderately severe acne. Its lead product, CTX-4430, is a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells. Celtaxsys also focuses on manipulating immune cell migration and activation to develop treatments for cancer, inflammatory conditions, and autoimmune diseases. Through its innovative approach, the company aims to provide effective therapies for patients suffering from rare and serious inflammatory disorders.

BioNTech is a Germany-based biotechnology company focused on developing cancer therapeutics and vaccines for infectious diseases. Its portfolio includes mRNA-based therapies to encode antigens and neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. The company maintains an oncology pipeline and collaborates on vaccines for infectious diseases, including a COVID-19 vaccine developed with Pfizer.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Viseon, Inc. is a medical device company based in Irvine, California, dedicated to advancing Minimally Invasive Spine Surgery (MISS) through innovative technology. Established in 2017 as a spin-out from Rebound Therapeutics Corporation, Viseon has developed the Voyant technology, which serves as a single-use, disposable alternative to traditional surgical microscopes, endoscopes, and loupes. This technology enhances surgical visualization by projecting the operative field onto a high-definition flat panel display, facilitating both in-room and remote observation. Viseon has made significant strides in product development, assembling a world-class Scientific Advisory Board and securing 13 patents to strengthen its intellectual property. The company is poised to begin human-use studies following a series of pre-clinical trials, aiming to improve procedural and clinical outcomes in spine surgery.

Rebound Therapeutics Corp. is a medical device company based in Irvine, California, focused on developing single-use, disposable devices that enhance access, imaging, and illumination during minimally invasive surgical procedures. Established in 2015, the company has made significant strides in product development, creating a unique range of devices aimed at improving procedural and clinical outcomes in various surgical fields, including neurosurgery, spine, orthopedic, thoracic, and general abdominal surgeries. Rebound Therapeutics has assembled a distinguished Scientific Advisory Board of leading physicians in minimally invasive surgery and has filed 14 patents to protect its innovative technologies. The company is also preparing for initial human-use trials following a series of successful pre-clinical studies. As of September 2019, Rebound operates as a subsidiary of Integra LifeSciences Holdings Corporation.

PatientsLikeMe, Inc. is a healthcare data-sharing platform founded in 2004 and based in Cambridge, Massachusetts. The company enables patients to share their symptoms, treatments, and health experiences, facilitating communication among patients, caregivers, physicians, researchers, and pharmaceutical companies. With over 600,000 members, it serves as a trusted source for real-world disease information across various health conditions, including cancer, mental health, and neurological disorders. PatientsLikeMe actively collaborates with major pharmaceutical companies and government organizations to integrate the patient perspective into research and public policy. The platform not only helps individuals find new treatment options and connect with others but also contributes to the development of new therapies through shared health data. The company has published more than 100 research studies, establishing itself as a clinically robust resource in the healthcare landscape. PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

AposHealth is focused on transforming the treatment of musculoskeletal conditions by addressing gait mechanics to alleviate pain and enhance mobility. Its flagship product, Apos®, is an FDA-cleared device designed to temporarily reduce knee pain associated with osteoarthritis, while also serving as a wellness tool for chronic lower back and hip pain. The Apos® system combines gait analysis with a personalized, foot-worn device and a tailored treatment plan. With a robust track record of over 110,000 patients treated and a 96 percent satisfaction rate, AposHealth is supported by numerous peer-reviewed studies that validate the effectiveness of its approach. By offering a drug-free and non-surgical solution, AposHealth empowers individuals to manage their discomfort and improve their quality of life.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

PatientsLikeMe, Inc. is a healthcare data-sharing platform founded in 2004 and based in Cambridge, Massachusetts. The company enables patients to share their symptoms, treatments, and health experiences, facilitating communication among patients, caregivers, physicians, researchers, and pharmaceutical companies. With over 600,000 members, it serves as a trusted source for real-world disease information across various health conditions, including cancer, mental health, and neurological disorders. PatientsLikeMe actively collaborates with major pharmaceutical companies and government organizations to integrate the patient perspective into research and public policy. The platform not only helps individuals find new treatment options and connect with others but also contributes to the development of new therapies through shared health data. The company has published more than 100 research studies, establishing itself as a clinically robust resource in the healthcare landscape. PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.